195 related articles for article (PubMed ID: 15176002)
41. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
Eilers G; Czaplinski JT; Mayeda M; Bahri N; Tao D; Zhu M; Hornick JL; Lindeman NI; Sicinska E; Wagner AJ; Fletcher JA; Mariño-Enriquez A
Mol Cancer Ther; 2015 Jun; 14(6):1346-53. PubMed ID: 25852058
[TBL] [Abstract][Full Text] [Related]
42. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.
Savoia P; Ortoncelli M; Quaglino P; Bernengo MG
Dermatol Surg; 2006 Aug; 32(8):1097-102. PubMed ID: 16918576
[No Abstract] [Full Text] [Related]
43. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
[TBL] [Abstract][Full Text] [Related]
44. Dermatofibrosarcoma protuberans: clinical series, national Danish incidence data and suggested guidelines.
Akram J; Wooler G; Lock-Andersen J
J Plast Surg Hand Surg; 2014 Feb; 48(1):67-73. PubMed ID: 23837507
[TBL] [Abstract][Full Text] [Related]
45. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
Ray-Coquard I; Blay JY
Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
[No Abstract] [Full Text] [Related]
46. Current treatment options for dermatofibrosarcoma protuberans.
Rutkowski P; Debiec-Rychter M
Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
[TBL] [Abstract][Full Text] [Related]
47. [Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans].
Moiseenko VM; Chudenko VA; Orlova RV; Imianitov EN; Matsko DE; Gafton GI; Kochnev VA; Protsenko SA; Mikhaĭlichenko TD; Nogaeva TKh
Vopr Onkol; 2008; 54(5):656-60. PubMed ID: 19069485
[No Abstract] [Full Text] [Related]
48. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
[TBL] [Abstract][Full Text] [Related]
49. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].
Fattoruso SI; Visca P; Lopez M
Clin Ter; 2008; 159(5):361-7. PubMed ID: 18998038
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery.
Jeon IK; Kim JH; Kim SE; Kim SC; Roh MR
J Dermatol; 2013 Apr; 40(4):288-9. PubMed ID: 23293988
[No Abstract] [Full Text] [Related]
51. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
[TBL] [Abstract][Full Text] [Related]
53. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.
Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS
JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909
[TBL] [Abstract][Full Text] [Related]
54. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
[TBL] [Abstract][Full Text] [Related]
55. Letter: clear margins after the use of imatinib mesylate prior to resection of extensive dermatofibrosarcoma protuberans.
Ortiz AE; Wu JJ; Linden KG
Dermatol Surg; 2008 Aug; 34(8):1151. PubMed ID: 18513297
[No Abstract] [Full Text] [Related]
56. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
Mizutani K; Tamada Y; Hara K; Tsuzuki T; Saeki H; Tamaki K; Matsumoto Y
Br J Dermatol; 2004 Jul; 151(1):235-7. PubMed ID: 15270901
[No Abstract] [Full Text] [Related]
57. Dermatofibrosarcoma protuberans is CD117 negative even after extreme antigen retrieval conditions.
Fernandez-Flores A
Rom J Morphol Embryol; 2007; 48(4):419-21. PubMed ID: 18060194
[TBL] [Abstract][Full Text] [Related]
58. [Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans].
Mátrai Z; Liszkay G; Plotár V; Orosz Z; Székely J; Hitre E; Bartal A; Langmár Z; Bocs K; Rényi Vámos F; Sávolt A; Tóth L
Orv Hetil; 2009 Oct; 150(41):1894-902. PubMed ID: 19801356
[TBL] [Abstract][Full Text] [Related]
59. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
Price VE; Fletcher JA; Zielenska M; Cole W; Viero S; Manson DE; Stuart M; Pappo AS
Pediatr Blood Cancer; 2005 May; 44(5):511-5. PubMed ID: 15503291
[TBL] [Abstract][Full Text] [Related]
60. [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors].
Bianchini L; Maire G; Pedeutour F;
Bull Cancer; 2007 Feb; 94(2):179-89. PubMed ID: 17337387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]